|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RSF1 |
Gene summary for RSF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RSF1 | Gene ID | 51773 |
| Gene name | remodeling and spacing factor 1 | |
| Gene Alias | HBXAP | |
| Cytomap | 11q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q05DG0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51773 | RSF1 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.96e-03 | 2.94e-01 | -0.1954 |
| 51773 | RSF1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.53e-05 | -5.60e-01 | -0.1207 |
| 51773 | RSF1 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.56e-04 | -3.61e-01 | 0.096 |
| 51773 | RSF1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 9.64e-04 | -4.50e-01 | 0.0338 |
| 51773 | RSF1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.28e-02 | -3.77e-01 | 0.0588 |
| 51773 | RSF1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.91e-03 | -4.73e-01 | 0.2585 |
| 51773 | RSF1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.16e-07 | -4.17e-01 | 0.3005 |
| 51773 | RSF1 | A015-C-203 | Human | Colorectum | FAP | 1.60e-27 | -2.38e-01 | -0.1294 |
| 51773 | RSF1 | A014-C-040 | Human | Colorectum | FAP | 1.15e-02 | 3.43e-03 | -0.1184 |
| 51773 | RSF1 | A002-C-201 | Human | Colorectum | FAP | 1.70e-09 | -1.22e-01 | 0.0324 |
| 51773 | RSF1 | A001-C-119 | Human | Colorectum | FAP | 1.84e-06 | 1.65e-01 | -0.1557 |
| 51773 | RSF1 | A001-C-108 | Human | Colorectum | FAP | 5.90e-14 | 5.12e-03 | -0.0272 |
| 51773 | RSF1 | A002-C-205 | Human | Colorectum | FAP | 1.28e-17 | -2.23e-02 | -0.1236 |
| 51773 | RSF1 | A015-C-006 | Human | Colorectum | FAP | 6.79e-12 | -1.78e-01 | -0.0994 |
| 51773 | RSF1 | A015-C-106 | Human | Colorectum | FAP | 1.57e-07 | -1.65e-02 | -0.0511 |
| 51773 | RSF1 | A002-C-114 | Human | Colorectum | FAP | 2.17e-15 | -1.34e-01 | -0.1561 |
| 51773 | RSF1 | A015-C-104 | Human | Colorectum | FAP | 1.49e-24 | -1.22e-01 | -0.1899 |
| 51773 | RSF1 | A001-C-014 | Human | Colorectum | FAP | 4.28e-10 | -7.66e-03 | 0.0135 |
| 51773 | RSF1 | A002-C-016 | Human | Colorectum | FAP | 8.29e-19 | -7.94e-02 | 0.0521 |
| 51773 | RSF1 | A015-C-002 | Human | Colorectum | FAP | 6.80e-10 | -1.26e-01 | -0.0763 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
| GO:20012356 | Breast | Precancer | positive regulation of apoptotic signaling pathway | 24/1080 | 126/18723 | 1.98e-07 | 1.01e-05 | 24 |
| GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
| GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
| GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
| GO:19030348 | Breast | Precancer | regulation of response to wounding | 19/1080 | 167/18723 | 3.60e-03 | 2.98e-02 | 19 |
| GO:200123314 | Breast | IDC | regulation of apoptotic signaling pathway | 82/1434 | 356/18723 | 6.27e-20 | 5.93e-17 | 82 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:200123514 | Breast | IDC | positive regulation of apoptotic signaling pathway | 31/1434 | 126/18723 | 4.13e-09 | 3.35e-07 | 31 |
| GO:005079214 | Breast | IDC | regulation of viral process | 36/1434 | 164/18723 | 6.55e-09 | 5.03e-07 | 36 |
| GO:009719114 | Breast | IDC | extrinsic apoptotic signaling pathway | 42/1434 | 219/18723 | 2.56e-08 | 1.73e-06 | 42 |
| GO:200123614 | Breast | IDC | regulation of extrinsic apoptotic signaling pathway | 32/1434 | 151/18723 | 1.07e-07 | 6.26e-06 | 32 |
| GO:005109814 | Breast | IDC | regulation of binding | 57/1434 | 363/18723 | 1.59e-07 | 8.76e-06 | 57 |
| GO:005110114 | Breast | IDC | regulation of DNA binding | 26/1434 | 118/18723 | 7.42e-07 | 3.40e-05 | 26 |
| GO:004852413 | Breast | IDC | positive regulation of viral process | 17/1434 | 65/18723 | 5.31e-06 | 1.75e-04 | 17 |
| GO:004206014 | Breast | IDC | wound healing | 55/1434 | 422/18723 | 7.27e-05 | 1.45e-03 | 55 |
| GO:20012385 | Breast | IDC | positive regulation of extrinsic apoptotic signaling pathway | 12/1434 | 48/18723 | 2.03e-04 | 3.32e-03 | 12 |
| GO:00433922 | Breast | IDC | negative regulation of DNA binding | 12/1434 | 52/18723 | 4.51e-04 | 6.07e-03 | 12 |
| GO:005110014 | Breast | IDC | negative regulation of binding | 25/1434 | 162/18723 | 5.98e-04 | 7.54e-03 | 25 |
| GO:190303413 | Breast | IDC | regulation of response to wounding | 24/1434 | 167/18723 | 2.07e-03 | 1.95e-02 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| TNF | TNFRSF1A | TNF_TNFRSF1A | TNF | Breast | ADJ |
| TNF | TNFRSF1B | TNF_TNFRSF1B | TNF | Breast | ADJ |
| TNFSF13B | TNFRSF17 | TNFSF13B_TNFRSF17 | BAFF | Breast | DCIS |
| TNFSF13B | TNFRSF13B | TNFSF13B_TNFRSF13B | BAFF | Breast | DCIS |
| TNFSF13B | TNFRSF13C | TNFSF13B_TNFRSF13C | BAFF | Breast | DCIS |
| TNF | TNFRSF1A | TNF_TNFRSF1A | TNF | Breast | DCIS |
| TNF | TNFRSF1B | TNF_TNFRSF1B | TNF | Breast | DCIS |
| TNFSF14 | TNFRSF14 | TNFSF14_TNFRSF14 | LIGHT | Breast | DCIS |
| TNFSF12 | TNFRSF12A | TNFSF12_TNFRSF12A | TWEAK | Breast | DCIS |
| TNF | TNFRSF1A | TNF_TNFRSF1A | TNF | Breast | Healthy |
| TNF | TNFRSF1B | TNF_TNFRSF1B | TNF | Breast | Healthy |
| TNFSF12 | TNFRSF12A | TNFSF12_TNFRSF12A | TWEAK | Breast | Healthy |
| TNFSF13B | TNFRSF17 | TNFSF13B_TNFRSF17 | BAFF | Breast | Healthy |
| TNFSF13B | TNFRSF13C | TNFSF13B_TNFRSF13C | BAFF | Breast | Healthy |
| TNFSF13B | TNFRSF17 | TNFSF13B_TNFRSF17 | BAFF | Breast | IDC |
| TNFSF13B | TNFRSF13C | TNFSF13B_TNFRSF13C | BAFF | Breast | IDC |
| TNFSF12 | TNFRSF12A | TNFSF12_TNFRSF12A | TWEAK | Cervix | ADJ |
| LTA | TNFRSF1A | LTA_TNFRSF1A | LT | Cervix | ADJ |
| LTA | TNFRSF1B | LTA_TNFRSF1B | LT | Cervix | ADJ |
| LTA | TNFRSF14 | LTA_TNFRSF14 | LT | Cervix | ADJ |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RSF1 | SNV | Missense_Mutation | c.1989A>C | p.Lys663Asn | p.K663N | Q96T23 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RSF1 | SNV | Missense_Mutation | novel | c.1274G>C | p.Cys425Ser | p.C425S | Q96T23 | protein_coding | tolerated_low_confidence(0.33) | benign(0.031) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
| RSF1 | SNV | Missense_Mutation | rs779258393 | c.3217G>A | p.Glu1073Lys | p.E1073K | Q96T23 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| RSF1 | SNV | Missense_Mutation | novel | c.334N>A | p.Leu112Ile | p.L112I | Q96T23 | protein_coding | tolerated(0.06) | benign(0.321) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RSF1 | SNV | Missense_Mutation | novel | c.3529G>C | p.Glu1177Gln | p.E1177Q | Q96T23 | protein_coding | deleterious(0.02) | possibly_damaging(0.725) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RSF1 | SNV | Missense_Mutation | c.2074G>C | p.Glu692Gln | p.E692Q | Q96T23 | protein_coding | deleterious(0.03) | benign(0.203) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RSF1 | SNV | Missense_Mutation | c.1645N>T | p.Asp549Tyr | p.D549Y | Q96T23 | protein_coding | deleterious_low_confidence(0) | benign(0.406) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| RSF1 | SNV | Missense_Mutation | c.2905N>C | p.Glu969Gln | p.E969Q | Q96T23 | protein_coding | deleterious(0.04) | possibly_damaging(0.734) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RSF1 | SNV | Missense_Mutation | novel | c.3947N>C | p.Gly1316Ala | p.G1316A | Q96T23 | protein_coding | tolerated_low_confidence(0.19) | benign(0.15) | TCGA-LL-A5YL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| RSF1 | insertion | In_Frame_Ins | novel | c.1529_1530insCCT | p.Arg510delinsSerLeu | p.R510delinsSL | Q96T23 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |